Stephanie Dancer

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.